The Longevity Reality Radar
46 approaches, rated by evidence.

Off-the-shelf CAR-T (TyU19)

Allogeneic 'off-the-shelf' CAR-T (TyU19). Autoimmune disease. Reviewed Jul 2026.

Donor cells cleared B cells and produced deep remission in early patients, with only six months of follow-up.

Stage
Phase 1
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
early patients
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

Donor-derived CAR-T cells that don't need to be made individually for each patient — a manufacturable, scalable version of the reset.

The evidence

Healthy-donor CD19 CAR-T achieved B-cell depletion within 2 weeks and deep remission over 6-month follow-up in early autoimmune patients.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Autoimmune disease

  • CAR-T for lupus and autoimmune diseaseGrade C, small cohorts. Phase 1/2.Drug-free remissions lasting past one to two years in small cohorts, with durability and infection risk still under study.